SLAM
TRVI icon

Swiss Life Asset Management’s Trevi Therapeutics TRVI Stock Holding History

Swiss Life Asset Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.66M Buy
+21,428
New +$240K 0.02% 459

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Swiss Life Asset Management's TRVI Position: Q1 2026 in Review

Swiss Life Asset Management opened a new position in Trevi Therapeutics (TRVI) in Q1 2026: 21,428 shares worth $3.66M. The stake represents 0.02% of the portfolio and ranks #459 among its holdings.

198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Swiss Life Asset Management held 21,428 shares of Trevi Therapeutics worth $3.66M as of Q1 2026.
  • Trevi Therapeutics was a new Swiss Life Asset Management position in Q1 2026.
  • Trevi Therapeutics made up 0.02% of Swiss Life Asset Management's portfolio in Q1 2026, its #459 holding.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Swiss Life Asset Management's 13F filing for Q1 2026, filed 14 May 2026.